OncoHost Study Offers New Insights into Resistance Mechanisms in Immunotherapy-Treated Lung Cancer Patients

Original source here

Plasma proteomics analysis reveals hallmarks of treatment resistance, paving the way for personalized strategies in NSCLC immunotherapy

On May 30, 2025, OncoHost, a technology company transforming the approach to precision oncology through proteomics and AI, announced the publication of a new study in the Journal for ImmunoTherapy of Cancer (JITC), titled “Decoding Resistance to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Comprehensive Analysis of Plasma Proteomics and Therapeutic Implications.” The open-access article was published May 22, 2025. The study provides a critical leap forward in understanding resistance to immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC)—one of the most pressing challenges in oncology today. Through a comprehensive bioinformatic analysis of pretreatment plasma proteomic profiles from 272 NSCLC patients, researchers identified key biological processes associated with resistance and revealed therapeutic targets that could inform future precision treatment strategies.

‍